Olaparib's Real-World impact on BRCA ovarian cancer examined

NCT ID NCT04532645

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked back at medical records of 342 women in Europe with advanced ovarian cancer and a BRCA gene mutation. All had taken the drug olaparib (Lynparza) as their first maintenance treatment after initial chemotherapy. Researchers tracked how long patients lived without their cancer getting worse and overall survival over three years. The goal was to see how well olaparib works in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Olaparib (Lynparza)
What this could lead to: If successful, this study could confirm how well olaparib works as a first-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer in real-world settings.
What could go wrong: This is an observational study that looks back at existing data, not a controlled trial. It cannot prove cause and effect, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARY CANCER

Contacts and locations

Show contact details

Locations

Research Site

Avignon, 84918, France
Research Site

Besançon, 25000, France
Research Site

Bordeaux, 33000, France
Research Site

Bourg-en-Bresse, 1012, France
Research Site

Calais, 62100, France
Research Site

Chambray-lès-Tours, 37175, France
Research Site

Epagny Metz-Tessy, 74370, France
Research Site

Grenoble, 38000, France
Research Site

Langon, 33210, France
Research Site

Lyon, 69004, France
Research Site

Nancy, 54000, France
Research Site

Paris, 75014, France
Research Site

Pierre-Bénite, 69310, France
Research Site

Roubaix, 59100, France
Research Site

Saint-Cloud, 92210, France
Research Site

Saint-Grégoire, 35760, France
Research Site

Suresnes, 92150, France
Research Site

Tours, 37000, France
Research Site

Villejuif, 94800, France
Research Site

Acquaviva delle Fonti, 70021, Italy
Research Site

Aviano, 33081, Italy
Research Site

Bari, 70124, Italy
Research Site

Bologna, 40138, Italy
Research Site

Cagliari, 09121, Italy
Research Site

Catania, 95126, Italy
Research Site

Florence, 50134, Italy
Research Site

Genova, 16132, Italy
Research Site

Milan, 20133, Italy
Research Site

Milan, 20141, Italy
Research Site

Milan, 20162, Italy
Research Site

Modena, 41124, Italy
Research Site

Naples, 80131, Italy
Research Site

Negrar, 37024, Italy
Research Site

Parma, 43126, Italy
Research Site

Roma, 00144, Italy
Research Site

Roma, 00168, Italy
Research Site

Torino, 10128, Italy
Research Site

Birmingham, United Kingdom
Research Site

Cambridge, United Kingdom
Research Site

Ediburgh, United Kingdom
Research Site

Glasgow, United Kingdom
Research Site

Guildford, United Kingdom
Research Site

Leeds, United Kingdom
Research Site

Liverpool, United Kingdom
Research Site

London, EC1A7BE, United Kingdom
Research Site

London, NW12BU, United Kingdom
Research Site

London, SW36JJ, United Kingdom
Research Site

London, W120HS, United Kingdom
Research Site

Maidstone, United Kingdom
Research Site

Manchester, United Kingdom
Research Site

Newcastle, United Kingdom
Research Site

Northampton, United Kingdom
Research Site

Nottingham, United Kingdom
Research Site

Portsmouth, United Kingdom
Research Site

Swansea, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.